The State government has approved the conduct of two clinical trials in the Andhra Medical College/ King George Hospital here, and a communiqué from the Directorate of Medical Education, Vijayawada, was received in this regard on Thursday.
The approval indicates Phase-2 clinical trial involved in usage of CRO Navitas Life Sciences 2-Deoxy- D-Glucose as an adjunctive therapy to standard care of acute treatment of moderate to severe COVID-19 cases. The study has the support of DRDO. The Principal of AMC, Prof. P.V. Sudhakar, has appointed Dr. Y. Gyana Sundar Raju, Prof of General Medicine, as the principal investigator for the study.
In the Phase 3 single blind randomised control study to determine the safety and immunogenicity of the coronavirus disease vaccine (COVISHIELD vaccine) of the Serum Institute of India will be done. This study has the support of ICMR. The Principal has appointed Dr. B. Devi Madhavi, Prof of Community Medicine, as the principal investigator for the vaccine trial.
A team of experts from various departments are co-investigators for the studies. “It is another advancement in the field of research and caters to the need of the hour in the COVID-19 pandemic situation,” he said.
The Collector, V. Vinay Chand, has congratulated the institute and wished success.
You have reached your limit for free articles this month.
To get full access, please subscribe.
Already have an account ? Sign in
Show Less Plan
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Faster pages
Move smoothly between articles as our pages load instantly.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Personalised recommendations
A select list of articles that match your interests and tastes.
Briefing
We brief you on the latest and most important developments, three times a day.
*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath